Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (NCT04562532)
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
🩺 Plain-English Summary (8th-Grade Level)
The aim of the TARGET-IV NA trial is to demonstrate the clinical non-inferiority of the Firehawk® rapamycin eluting stent system in comparison to currently approved 2nd generation DES for the treatment of subjects with ischemic heart disease (NSTEMI, recent STEMI (\>24 hours from initial presentation and in whom enzyme levels have peaked), unstable angina, and stable coronary disease), with atherosclerotic target lesion(s) in coronary arteries with visually estimated reference vessel diameters ≥2.25 mm and ≤4.0 mm.
Who can join: Review the eligibility criteria below.
Location: Cardiology PC — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (57 Sites)
Showing the first 25 of 57 sites.
- Cardiology PC — Birmingham, Alabama
- Mercy Gilbert Medical Center — Gilbert, Arizona
- UC San Diego School of Medicine — La Jolla, California
- Riverside Community Hospital — Riverside, California
- Sharp Memorial Hospital — San Diego, California
- Santa Barbara Cottage Hospital — Santa Barbara, California
- Yale New Heaven Hospital — New Haven, Connecticut
- JFK Medical Center — Atlantis, Florida
- CCC Research - Countryside — Clearwater, Florida
- Clearwater Cardiovascular Consultants — Clearwater, Florida
- Memorial Hospital Jacksonville — Jacksonville, Florida
- Atlanta Veterans Affairs Medical Center — Decatur, Georgia
- Elkhart General Hospital — Elkhart, Indiana
- St. Vincent Heart Center of Indiana — Indianapolis, Indiana
- The University of Kansas Medical Center — Kansas City, Kansas
- Eastern Maine Medical Center-Northern Light Cardiology — Bangor, Maine
- Massachusetts General Hospital — Boston, Massachusetts
- Brigham and Womens Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center, Inc. — Boston, Massachusetts
- St. Joseph Mercy Hospital — Ann Arbor, Michigan
- McLaren Bay — Bay City, Michigan
- McLaren Greater Lansing — Lansing, Michigan
- McLaren Northern Michigan — Petoskey, Michigan
- Metropolitan Heart Vascular Institute — Coon Rapids, Minnesota
- Minneapolis Heart Institute Foundation — Minneapolis, Minnesota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Coronary Artery Disease
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended — Stanford, California
- Genomic Investigation of Cardiovascular Diseases — La Jolla, California
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health — Boston, Massachusetts
- A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD — Mobile, Alabama
- Precision PCI Registry — Gainesville, Florida
Explore by condition: All Coronary Artery Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.